

COMPANY RELEASE

Crafton Biotechnology Co., Ltd. Announces the Appointment of New Chief Technology and Chief Business Officer

Nagoya, Japan | February 18, 2025

Crafton Biotechnology Co., Ltd. (Crafton), a privately held biotech based in Nagoya, Japan is pleased to announce the appointment of Kelvin Chan, PhD as the new Chief Technology Officer (CTO) and Chief Business Officer (CBO). Dr. Chan will be responsible for overseeing Crafton's technology and business strategy, with a focus on advancing the company's pioneering PureCap® and chemically synthesized mRNA platform, as well as its pipeline of mRNA medicines.

Dr. Chan joins Crafton with extensive experience in cross-border biotechnology innovation and leadership. He brings a deep understanding of mRNA, having previously been the founding Director of Business Development at a mRNA Contract Development and Manufacturing Organization, Kudo Biotechnology. He was also formerly Director of Business Development at a mRNA company, RVAC Medicines. Dr. Chan's expertise will help drive Crafton's mission of transforming the treatment landscape for diseases that have historically been difficult to treat, enabled by Crafton's best-in-class and first-in-class technology platforms.

"I am honored to join Crafton and work alongside our exceptional team. Crafton leverages a proprietary suite of technologies that promises to solve for unmet clinical needs in a wide spectrum of therapeutic areas. I look forward to bringing our innovations in mRNA to the global stage and to our patients," said Dr. Chan.

"We are happy to have Dr. Chan on board this exciting journey. His addition to our C-Suite will definitely help us shape our strategy and growth going forward," commented President and CEO Hayato Watanabe, CFA.

